[go: up one dir, main page]

MX2011009213A - 8-substituted quinolines and related analogs as sirtuin modulators. - Google Patents

8-substituted quinolines and related analogs as sirtuin modulators.

Info

Publication number
MX2011009213A
MX2011009213A MX2011009213A MX2011009213A MX2011009213A MX 2011009213 A MX2011009213 A MX 2011009213A MX 2011009213 A MX2011009213 A MX 2011009213A MX 2011009213 A MX2011009213 A MX 2011009213A MX 2011009213 A MX2011009213 A MX 2011009213A
Authority
MX
Mexico
Prior art keywords
sirtuin
diseases
disorders
substituted quinolines
related analogs
Prior art date
Application number
MX2011009213A
Other languages
Spanish (es)
Inventor
Chi B Vu
Rebecca L Casaubon
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of MX2011009213A publication Critical patent/MX2011009213A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)

Abstract

Provided herein are 8-substituted quinolines and related analogues as sirtuin-modulating compounds of Structural Formula (I) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
MX2011009213A 2009-03-02 2010-03-02 8-substituted quinolines and related analogs as sirtuin modulators. MX2011009213A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15674909P 2009-03-02 2009-03-02
PCT/US2010/025963 WO2010101949A1 (en) 2009-03-02 2010-03-02 8-substituted quinolines and related analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
MX2011009213A true MX2011009213A (en) 2011-12-14

Family

ID=42709991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009213A MX2011009213A (en) 2009-03-02 2010-03-02 8-substituted quinolines and related analogs as sirtuin modulators.

Country Status (11)

Country Link
EP (1) EP2403833A4 (en)
JP (1) JP2012519211A (en)
KR (1) KR20110128908A (en)
CN (1) CN102414180A (en)
AU (1) AU2010221417A1 (en)
BR (1) BRPI1011477A2 (en)
CA (1) CA2754058A1 (en)
EA (1) EA201171098A1 (en)
IL (1) IL214943A0 (en)
MX (1) MX2011009213A (en)
WO (1) WO2010101949A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110007235A (en) 2008-05-01 2011-01-21 서트리스 파마슈티컬즈, 인코포레이티드 Quinoline and related analogs as sirtuin modulators
KR20110036602A (en) 2008-07-03 2011-04-07 서트리스 파마슈티컬즈, 인코포레이티드 Benzimidazole and related analogs as sirtuin modulators
BRPI0919389A2 (en) 2008-09-29 2016-01-19 Sirtris Pharmaceutical Inc chromone analogues as sirtuin modulators
CN102725291B (en) 2009-10-29 2016-12-21 西特里斯药业公司 Bicyclic pyridine and relevant analog as Sirtuin regulator
CN103002738A (en) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 Chemical compounds, compositions and methods for kinase modulation
AU2012230503B2 (en) 2011-03-18 2016-07-07 Bayer Intellectual Property Gmbh N-(3-carbamoylphenyl)-1H-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests
CN102250151B (en) * 2011-05-17 2013-11-06 中国科学院化学研究所 2-arimid-8-benzimidazol quinoline transition metal compound and preparation method and use thereof
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
KR20140077963A (en) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
WO2013059589A1 (en) * 2011-10-20 2013-04-25 Sirtris Pharmaceuticals, Inc. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EA201491667A1 (en) 2012-03-13 2015-03-31 Басф Се FUNGICIDE PYRIMIDINE COMPOUNDS
HK1207317A1 (en) 2012-11-20 2016-01-29 霍夫曼-拉罗奇有限公司 Substituted 1,6-naphthyridines
AU2014241065B2 (en) 2013-03-14 2017-08-31 Merck Patent Gmbh Glycosidase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN105339368B (en) 2013-06-04 2017-08-15 拜耳制药股份公司 Imidazo [1,2 a] pyridine of 3 aryl substitution and application thereof
TWI529171B (en) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 1,7-naphthyridine derivatives
US20160221964A1 (en) 2013-09-16 2016-08-04 Basf Se Fungicidal pyrimidine compounds
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
JP6112724B2 (en) * 2013-10-31 2017-04-12 日本化薬株式会社 1,5-naphthyridine derivative and insecticide comprising the same as an active ingredient
JP6229056B2 (en) 2013-11-12 2017-11-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Pyrido [4,3-b] pyrazine-2-carboxamide as a neurogenesis agent for the treatment of neurodegenerative diseases
WO2015107133A1 (en) 2014-01-20 2015-07-23 Bayer Cropscience Ag Quinoline derivatives as insecticides and acaricides
WO2015124544A1 (en) 2014-02-19 2015-08-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
US9771372B2 (en) 2014-05-23 2017-09-26 Active Biotech Ab Compounds useful as S100-inhibitors
EP3169678A1 (en) * 2014-07-17 2017-05-24 Merck Patent GmbH Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
CN106573915B (en) 2014-08-01 2020-12-25 纽韦卢森公司 Compounds active against bromodomains
KR102043337B1 (en) 2014-08-28 2019-11-11 아셰뉴론 에스아 Glycosidase inhibitors
EP3227287B1 (en) 2014-12-02 2019-08-07 Bayer Pharma Aktiengesellschaft Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
CN104592109A (en) * 2015-01-19 2015-05-06 湖南华腾制药有限公司 Method for preparing 8-bromoquinoline derivative
MX2017010230A (en) * 2015-02-11 2017-12-04 Basilea Pharm Int Ag Substituted mono- and polyazanaphthalene derivatives and their use.
US10556902B2 (en) 2016-02-25 2020-02-11 Asceneuron Sa Glycosidase inhibitors
CN109071526B (en) 2016-02-25 2023-02-28 阿森纽荣股份公司 Acid addition salts of piperazine derivatives
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. Linear glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
MX2021002111A (en) 2018-08-22 2021-07-16 Asceneuron S A Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors.
KR20210143783A (en) * 2019-02-28 2021-11-29 케자르 라이프 사이언스 Thiazole derivatives as inhibitors of protein secretion
CN110964011B (en) * 2019-12-16 2022-06-21 诚达药业股份有限公司 Synthetic method of 8-chloro-1, 7-naphthyridine-3-formaldehyde
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
EP4620469A3 (en) 2020-07-02 2025-10-01 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (en) 2021-02-25 2023-07-05 Incyte Corp SPIROCYCLIC LACTAMS AS JAK2 INHIBITORS V617F
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CN119173514A (en) 2022-03-17 2024-12-20 因赛特公司 Tricyclic urea compounds as JAK2 V617F inhibitors
WO2024059212A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same
WO2024059216A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20250174937A (en) * 2023-04-23 2025-12-15 쑤저우 젠하우스 바이오 컴퍼니 리미티드 Amide compounds, pharmaceutical compositions containing the same, and uses thereof
CN117362286B (en) * 2023-12-08 2024-03-12 清华大学 Compounds with SIRT6 agonistic activity and their uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037633B1 (en) * 1997-12-11 2003-09-10 Biochem Pharma Inc. Antiviral compounds
FR2827599A1 (en) * 2001-07-20 2003-01-24 Neuro3D Treating central nervous system disorders, e.g. anxiety, depression, schizophrenia or pain, using new or known 2-substituted quinoline or quinoxaline derivatives having xanthenuric acid modulating action
SE0103649D0 (en) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
JP2006519846A (en) * 2003-03-10 2006-08-31 シェーリング　コーポレイション Heterocyclic kinase inhibitors: methods of use and synthesis
MX2007001267A (en) * 2004-08-03 2007-07-11 Serenex Inc 2, 8-disubstituted naphthyridine derivatives.
AU2006218405A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline derivatives as sirtuin modulators
EP2250152A1 (en) * 2008-02-28 2010-11-17 Novartis AG Quinolines as inhibitors of farnesyl pyrophosphate synthase
KR20110007235A (en) * 2008-05-01 2011-01-21 서트리스 파마슈티컬즈, 인코포레이티드 Quinoline and related analogs as sirtuin modulators
BRPI0919389A2 (en) * 2008-09-29 2016-01-19 Sirtris Pharmaceutical Inc chromone analogues as sirtuin modulators

Also Published As

Publication number Publication date
KR20110128908A (en) 2011-11-30
EP2403833A4 (en) 2012-08-29
JP2012519211A (en) 2012-08-23
CA2754058A1 (en) 2010-09-10
EA201171098A1 (en) 2012-04-30
AU2010221417A1 (en) 2011-09-22
WO2010101949A1 (en) 2010-09-10
IL214943A0 (en) 2011-11-30
BRPI1011477A2 (en) 2016-03-22
CN102414180A (en) 2012-04-11
EP2403833A1 (en) 2012-01-11

Similar Documents

Publication Publication Date Title
MX2011009213A (en) 8-substituted quinolines and related analogs as sirtuin modulators.
EP2342188A4 (en) Chromenone analogs as sirtuin modulators
MX2010012961A (en) Imidazopyridine and related analogs as sirtuin modulators.
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
UA104447C2 (en) Thiazolopyridine sirtuin modulating compounds
MX2011006084A (en) Isoindolinone and related analogs as sirtuin modulators.
MX2011006475A (en) Phthalazinone and related analogs as sirtuin modulators.
IN2012DN03799A (en)
MY149316A (en) Sirtuin modulating imidazohiazole compounds
MX2010004965A (en) Amide derivatives as sirtuin modulators.
MX2009013977A (en) Sirtuin modulating thiazolopyridine compounds.
MX2010005186A (en) Solubilized thiazolopyridines.
AU2014265671A8 (en) Substituted bridged urea analogs as sirtuin modulators
WO2006094209A3 (en) N-benzimidazolylalkyl-substituted amide sirtuin modulators
EA201170137A1 (en) BENZIMIDAZLES AND RELATED ANALOGUES AS SIRTUIN MODULATORS
PH12017500913A1 (en) Substituted bridged urea analogs as sirtuin modulators
CR9347A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
WO2008100376A3 (en) Truncation variants of sirt1 and methods of use thereof
WO2009085226A3 (en) Inhibitors of cdc2-like kinases (clks) and methods of use thereof
MX2011009493A (en) Compounds for the treatment of metabolic disorders.
WO2006094210A3 (en) Tetrahydroquinoxalinone sirtuin modulators
WO2006094246A3 (en) N-arylmethyl benzamide sirtuin modulators
GB201116017D0 (en) Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
WO2016081692A3 (en) Substituted bridged urea analogs as sirtuin modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal